NanoString Technologies
Nov 30, 2016

NanoString Technologies Highlights Advances in Precision Oncology at the 58th Annual Meeting of the American Society of Hematology

Abstracts Demonstrate the Value of the nCounter Platform for Disease Characterization, Translational Research and Diagnostic Applications in Hematology

SEATTLE, Nov. 30, 2016 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced the highlights of numerous advances in precision oncology and hematology using the nCounter® platform that will be presented at the Annual Meeting of the American Society of Hematology (ASH).  

"We're excited by the volume and impact of the important translational research that our customers and collaborators are presenting at the meeting of the American Society of Hematology," said Brad Gray, president and chief executive officer of NanoString Technologies. "This research includes significant advances in subtyping lymphomas and optimizing regimens to achieve better clinical outcomes."

The ASH Annual Meeting, being held December 3-6, in San Diego, will include at least seven oral presentations and nine posters that demonstrate the unique capabilities and robust performance of the nCounter platform.  In particular, several abstracts provide additional insights on the development and performance of NanoString's assay in development for subtyping lymphoma.

In lymphoma, NanoString and its collaborators are presenting results generated using the nCounter-based Lymphoma Subtyping Test showing its analytical robustness and clinical relevance, including:

The 2016 ASH abstracts describe research and clinical applications that underscore the diverse capabilities of the nCounter platform, which NanoString will showcase at booth #3651.

Abstract #TitleHyperlink
2933Analytical Validation of the nCounter®-based Lymphoma Subtyping Test (LST) for Cell-of-Origin (COO) Identification in Formalin-Fixed Paraffin-Embedded (FFPE) Diffuse Large B-Cell Lymphoma (DLBCL) Specimenshttps://ash.confex.com/ash/2016/webprogram/Paper93666.html
3035Lenalidomide Combined with R-CHOP (R2CHOP) Overcomes Negative Prognostic Impact of ABC Molecular Subtype in Newly Diagnosed Diffuse Large B-Cell Lymphomahttps://ash.confex.com/ash/2016/webprogram/Paper95550.html
470Obinutuzumab or Rituximab Plus CHOP in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma: Final Results from an Open-Label, Randomized Phase 3 Study (GOYA)https://ash.confex.com/ash/2016/webprogram/Paper96159.html
471First Analysis of an International Double-Blind Randomized Phase III Study of Lenalidomide Maintenance in Elderly Patients with DLBCL Treated with R-CHOP in First Line, the Remarc Study from Lysahttps://ash.confex.com/ash/2016/webprogram/Paper91527.html
474Lenalidomide Maintenance Significantly Improves Survival Figures in Patients with Relapsed Diffuse Large B-Cell Lymphoma (rDLBCL) Who Are Not Eligible for Autologous Stem Cell Transplantation (ASCT): Final Results of a Multicentre Phase II Trialhttps://ash.confex.com/ash/2016/webprogram/Paper96221.html
152Integrating Genomic Alterations in Diffuse Large B-Cell Lymphoma Identifies New Relevant Pathways and Potential Therapeutic Targets https://ash.confex.com/ash/2016/webprogram/Paper94639.html
2935Whole-Exome Analysis Reveals Novel Somatic Genomic Alterations Associated with Cell of Origin in Diffuse Large B-Cell Lymphomahttps://ash.confex.com/ash/2016/webprogram/Paper96566.html
1107Pembrolizumab in Relapsed/Refractory Classical Hodgkin Lymphoma: Primary End Point Analysis of the Phase 2 Keynote-087 Studyhttps://ash.confex.com/ash/2016/webprogram/Paper97284.html
619Phase 1b Study of Pembrolizumab in Patients with Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma: Results from the Ongoing Keynote-013 Trialhttps://ash.confex.com/ash/2016/webprogram/Paper93580.html
918A Novel Anti-Lymphoma Immune Evasion Mediated By the Interaction Between PD-1 Enriched NK-Cells and CD163+PD-L1+PD-L2+ Tumor Associated Macrophages, That Is More Prominent in Hodgkin Lymphoma Than Diffuse Large B-Cell Lymphomahttps://ash.confex.com/ash/2016/webprogram/Paper92109.html
4576Differential Expression of Immunity Related Genes and Early Prediction of Severe Graft Versus Host Disease after Allogeneic Hematopoietic Cell Transplantationhttps://ash.confex.com/ash/2016/webprogram/Paper97711.html
1954Transcriptional Characterization of Myelofibrotic Bone Marrow Microenvironment Reveals Distinct Tumor Microenvironment in JAK2+ and Calr+ PMF Marrowshttps://ash.confex.com/ash/2016/webprogram/Paper97124.html
1664Microvesicles microRNAs Reflect and Affect Progression of Acute Myeloid Leukemia and Could Serve As a Biomarker of Disease Dynamicshttps://ash.confex.com/ash/2016/webprogram/Paper90648.html
3285Integrative Network Analysis of Newly Diagnosed Multiple Myeloma Identifies a Novel RNA-Seq Based High Risk gene Signaturehttps://ash.confex.com/ash/2016/webprogram/Paper97575.html

About NanoString Technologies, Inc.
NanoString Technologies provides life science tools for translational research and molecular diagnostic products. The company's nCounter® Analysis System has been employed in life sciences research since it was first introduced in 2008 and has been cited in more than 1,350 peer-reviewed publications. The nCounter Analysis System offers a cost-effective way to easily profile the expression of hundreds of genes, proteins, miRNAs, or copy number variations, simultaneously with high sensitivity and precision, facilitating a wide variety of basic research and translational medicine applications, including biomarker discovery and validation. The company's technology is also being used in diagnostics. The Prosigna® Breast Cancer Prognostic Gene Signature Assay together with the nCounter Dx Analysis System is FDA 510(k) cleared for use as a prognostic indicator for distant recurrence of breast cancer. In addition, the company is collaborating with multiple biopharmaceutical companies in the development of companion diagnostic tests for various cancer therapies, helping to realize the promise of precision oncology.

For more information, please visit www.nanostring.com.

The NanoString Technologies logo, NanoString, NanoString Technologies, nCounter and Prosigna are registered trademarks or trademarks of NanoString Technologies, Inc. in various jurisdictions.

Contact:



Doug Farrell

Vice President, Investor Relations & Corporate Communications

dfarrell@nanostring.com

Phone: 206-602-1768

Primary Logo

Source: NanoString Technologies

News Provided by Acquire Media